The DOI matches its Crossref record; 313 of the 313 references it cites were found in a registry or an index.
NRF2 as a Therapeutic Target in Neurodegenerative Diseases
Open accessAbstract
Increased reactive oxygen species production and oxidative stress have been implicated in the pathogenesis of numerous neurodegenerative conditions including among others Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Friedrich’s ataxia, multiple sclerosis, and stroke. The endogenous antioxidant response pathway protects cells from oxidative stress by increasing the expression of cytoprotective enzymes and is regulated by the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2). In addition to regulating the expression of antioxidant genes, NRF2 has also been shown to exert anti-inflammatory effects and modulate both mitochondrial function and biogenesis. This is because mitochondrial dysfunction and neuroinflammation are features of many neurodegenerative diseases as well NRF2 has emerged as a promising therapeutic target. Here, we review evidence for a beneficial role of NRF2 in neurodegenerative conditions and the potential of specific NRF2 activators as therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another Nrf2 activating compound is Centella asiatica extracts, which can activate Nrf2 in neuroblastoma cells, isolated primary neurons and in the brains of AD and aging mouse models. This activation improved mitochondrial and cognitive function, and enhanced synaptic density [113,114,115].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kouchaki, E., Afarini, M., Abolhassani, J., Mirhosseini, N. Z., Bahmani, F., Masoud, S. A., & Asemi, Z. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy116 · Cited by 49
RetractedLozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070 · cited 1×
“Stroke is the second leading cause of death worldwide and the leading cause of acquired adult disability (Lozano et al., 2012; Murray et al., 2012).”
BackgroundMurray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888 · cited 1×
“Stroke is the second leading cause of death worldwide and the leading cause of acquired adult disability (Lozano et al., 2012; Murray et al., 2012).”
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. “., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,698
Oxyl radicals, redox-sensitive signalling cascades and antioxidants
Genestra, M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.009 · Cited by 4,930
Compston, A., & Coles, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,699
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress
Nguyen, T., Nioi, P., & Pickett, C. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r900010200 · Cited by 2,655
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Research works printed but not linked: 1
- Reata Pharmaceuticals. (2019). Reata announces positive topline results from the MOXIe registrational trial of omaveloxolone in patients with Friedreich’s ataxia. Los Angeles, CA: Globe News Wire.
Cited by
Sorted by citations
Buccellato, F. R., D’Anca, M., Fenoglio, C., Scarpini, E., & Galimberti, D. (2021) · Antioxidants · doi:10.3390/antiox10091353 · Cited by 179
Yan, L., Guo, M.-S., Zhang, Y., Yu, L., Wu, J.-M., Tang, Y., Ai, W., Zhu, F.-D., Law, B. Y.-K., Chen, Q., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5288698 · Cited by 97
Wong, J. H., Barron, A. M., & Abdullah, J. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.687935 · Cited by 79
Parikh, B. H., Liu, Z., Blakeley, P., Lin, Q., Singh, M., Ong, J. Y., Ho, K. H., Lai, J. W., Bogireddi, H., Tran, K. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30474-6 · Cited by 54
Piovan, A., Battaglia, J., Filippini, R., Dalla Costa, V., Facci, L., Argentini, C., Pagetta, A., Giusti, P., & Zusso, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.724993 · Cited by 31
Metadata
- Authors
- Brandes, M. S., & Gray, N. E.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Gray, Nora E.
- Venue
- ASN Neuro
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 12
- Issue
- 1
- Pages
- 1759091419899782-1759091419899782
- ISSN
- 1759-0914 (ISSN-L)
- PMC
- PMC6977098
- OpenAlex
- W3002509135
- Cited by
- 297
- References
- 313
- Citations by year
- 2026: 45 · 2025: 52 · 2024: 40 · 2023: 42 · 2022: 43 · 2021: 57 · 2020: 18
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ASN NEURO (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of General Medical Sciences (UL1GM118964, TL4GM118965, RL5GM118963)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- Nrf2, neurodegenerative diseases, oxidative stress, reactive oxygen species, Nrf2 activators, neuroinflammation, mitochondrial dysfunction, mitochondrial biogenesis, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, stroke
- MeSH terms
- Animals, Anti-Inflammatory Agents, Antioxidants, Humans, Drug Delivery Systems, Reactive Oxygen Species, Oxidative Stress, Neurodegenerative Diseases, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
